

Neurochemical Alterations: The Paradox of Psychoactive Drug Consumption

Zenli Chen*

Department of Psychopharmacology, Peking University, Beijing, China

DESCRIPTION

Psychoactive drugs are substances that affect the brain, altering mood, perception and behavior. They are used for various reasons, medical treatments, recreation and even spiritual purposes. However, their use can lead to significant risks including addiction health complications and social problems. Understanding their effects risks and role in society is important for making informed decisions about their use and managing their impact [1].

Types of psychoactive drugs

Psychoactive drugs can be broadly classified into four categories: stimulants depressants hallucinogens and opioids. Each category has distinct effects on the Central Nervous System (CNS) and produces different psychological and physiological responses [2].

Stimulants: It increase brain activity promoting alertness energy and euphoria. While stimulants are often used for performance improvement chronic use can result in anxiety paranoia and addiction [3].

Depressants: It slow down brain function inducing relaxation and reducing anxiety. While prescribed for medical conditions like anxiety and insomnia their misuse can lead to respiratory depression memory loss and addiction.

Hallucinogens: Alter perception causing sensory distortions and altered states of consciousness. Although some have therapeutic potential for mental health conditions their unpredictable effects can trigger anxiety paranoia and psychosis in some users.

Opioids: Opioids are powerful painkillers that bind to receptors in the brain reducing pain and inducing feelings of euphoria. While need in pain management opioids are highly addictive and have led to a global crisis of overdose and death [4].

Psychological and physiological effects

Psychoactive drugs can have varying effects on both the mind and body. Stimulants can increase heart rate and blood pressure while depressants may lower heart rate and breathing. The

psychological effects such as euphoria from stimulants or relaxation from depressants can be appealing but they come with the risk of addiction and long-term mental health issues.

The effects of hallucinogens are less predictable as they can induce vivid hallucinations or emotional experiences that can be either positive or negative. While some believe hallucinogens may offer therapeutic benefits they carry the risk of triggering mental health disorders especially in individuals predisposed to conditions like schizophrenia [5].

Opioids while effective at relieving pain pose severe risks. Addiction to opioids can develop quickly and overdose is a major concern. The opioid epidemic has highlighted the dangers of misuse and the challenges in managing pain without increasing the risk of addiction [6].

Addiction and dependency

One of the most concerning aspects of psychoactive drug use is the potential for addiction. Dependency occurs when the body becomes reliant on a substance to function leading to withdrawal symptoms when the drug is not available. Many psychoactive substances particularly opioids stimulants and alcohol have a high potential for addiction [7].

Addiction affects not only the individual but also their family community and society as a whole. Treating addiction often requires a multi-faceted approach including therapy support groups and sometimes medication. Programs that address prevention and provide treatment options are critical in combating the widespread issues of drug dependence [8].

The role of psychoactive drugs in society

Psychoactive drugs have long been part of human society whether for medicinal recreational or religious purposes. While many psychoactive drugs have valid medical uses their misuse can lead to significant social and health problems including family breakdown financial instability and criminal behavior. In addition, the societal stigma surrounding drug use can prevent people from seeking help for addiction [9].

Correspondence to: Zenli Chen, Department of Psychopharmacology, Peking University, Beijing, China, E-mail: zhen@lnu.edu.cn

Received: 27-Nov-2024, Manuscript No. JPR-24-36406; **Editor assigned:** 29-Nov-2024, PreQC No. JPR-24-36406 (PQ); **Reviewed:** 13-Dec-2024, QC No. JPR-24-36406; **Revised:** 20-Dec-2024, Manuscript No. JPR-24-36406 (R); **Published:** 27-Dec-2024, DOI: 10.35248/JPR.24.08.233

Citation: Chen Z (2024). Neurochemical Alterations: The Paradox of Psychoactive Drug Consumption. J Pharma Reports. 08:233.

Copyright: © 2024 Chen Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Governments and health organizations face the challenge of balancing the legitimate medical uses of psychoactive drugs with the risks they pose when misused. Policies should aim to reduce harm through education regulation and providing support for addiction treatment. Harm-reduction strategies such as needle exchange programs and supervised consumption sites have been shown to mitigate some of the negative effects of drug use in society.

Psychoactive drugs can have profound effects on both individual health and society at large. While some drugs have need medical benefits their misuse carries significant risks including addiction overdose and long-term health issues. Society must continue to balance the therapeutic uses of psychoactive substances with the potential harms they cause focusing on prevention education and accessible treatment for addiction. It is important to foster a better understanding of these substances to minimize their negative impact while harnessing their benefits for medical and therapeutic purposes [10].

REFERENCES

1. Albers MM, Johnson W, Vivian V, Jackson RD. Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. *Bone*. 1991;12(1):39-42.
2. Feger M, Ewendt F, Strotmann J, Schäffler H, Kempe-Teufel D, Glosse P, et al. Glucocorticoids dexamethasone and prednisolone suppress Fibroblast Growth Factor 23 (FGF23). *J Mol Med*. 2021; 99:699-711.
3. Langenbach F, Handschel J. Effects of dexamethasone, ascorbic acid and β -glycerophosphate on the osteogenic differentiation of stem cells *in vitro*. *Stem Cell Res Ther*. 2013;4:1-7.
4. Liu Y, Chen Y, Zhao H, Zhong L, Wu L, Cui L. Effects of different doses of dexamethasone on bone qualities in rats. *J Biomed Eng*. 2011;28(4):737-743.
5. Maggiorini M, Brunner-La Rocca HP, Peth S, Fischler M, Böhm T, Bernheim A, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: A Randomized trial. *Ann Intern Med*. 2006;145(7):497-506.
6. Rasmussen SA, Daenzer JM, MacWilliams JA, Head ST, Williams MB, Geurts AM, et al. A galactose-1-phosphate uridylyltransferase-null rat model of classic galactosemia mimics relevant patient outcomes and reveals tissue-specific and longitudinal differences in galactose metabolism. *J Inherit Metab Dis*. 2020;43(3):518-528.
7. Wells WW, Pittman TA, Wells HJ, Egan TJ. The isolation and identification of galactitol from the brains of galactosemia patients. *J Biol Chem*. 1965;240(3):1002-1004.
8. Birlouez-Aragon I, Alloussi S. Effect of prolonged galactose consumption on galactose tolerance in young healthy humans. *Ann Nutr Metab*. 1990;34(1):1-7.
9. Hughes J, Ryan S, Lambert D, Geoghegan O, Clark A, Rogers Y, et al. Outcomes of siblings with classical galactosemia. *J Pediatr*. 2009;154(5):721-726.
10. Böhles H, Wenzel D, Shin YS. Progressive cerebellar and extrapyramidal motor disturbances in galactosaemic twins. *Eur J Pediatr*. 1986;145(5):413-417.